Tonix Pharmaceuticals Holding Corp. — Q2 2014 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2014. Tonix was a clinical-stage pharmaceutical company with no commercial products or revenue; its development pipeline focused on CNS disorders. Unless noted otherwise, financial amounts below are in millions of dollars.
Financial performance and position
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $4.075 | $0.944 | $7.625 | $1.685 |
| General and administrative expense | $1.974 | $1.142 | $3.593 | $2.402 |
| Operating loss | $(6.049) | $(2.086) | $(11.218) | $(4.087) |
| Net loss | $(6.044) | $(2.086) | $(11.208) | $(4.087) |
| Basic and diluted loss per share | $(0.61) | $(0.95) | $(1.20) | $(1.88) |
- Six-month operating cash use was $9.763, compared with $2.123 a year earlier. Investing cash use was $0.107; financing provided $45.543, chiefly from the January equity offering and warrant exercises.
- At June 30, cash was $43.870; working capital was approximately $42.445. Total liabilities were $2.401, including $0.280 of related-party promissory notes. Total assets were $45.065 and stockholders’ equity was $42.664. The notes were repaid in July and August 2014.
- No gross-profit or operating-margin measure is meaningful because the company had no revenue.
Changes versus the prior comparable period
- Q2 R&D expense rose 333% and six-month R&D expense rose 353%, primarily reflecting increased TNX-102 SL manufacturing and clinical work. Six-month G&A expense increased 50%.
- Six-month net loss increased to $11.208 from $4.087, while loss per share narrowed, reflecting a substantially larger weighted-average share count following equity issuance and warrant exercises.
- Cash increased from $8.202 at year-end 2013 to $43.870 at June 30, 2014, mainly due to $40.654 net proceeds from the January offering and $4.889 from warrant exercises.
Outlook, risks, and notable items
- Management stated that existing funds were expected to cover operating expenses and capital requirements for at least 12 months; it also expected R&D spending to increase significantly over the next 12–24 months. A July 2014 registered direct offering subsequently added approximately $7.2 million net.
- Management expected Q4 2014 topline results from the TNX-102 SL fibromyalgia BESTFIT trial, planned to begin a PTSD Phase 2 trial in Q4 2014, and expected to file an IND for TNX-201 in Q4 2014, with a Phase 1 trial anticipated in Q1 2015. These are stated plans and expectations, not assured outcomes.
- Key risks include clinical efficacy and safety, patient recruitment and trial delays, FDA review and approval, commercialization, and the need for further financing. If financing is unavailable or inadequate, Tonix may need to reduce or delay programs or seek partners, potentially relinquishing product rights.
- Tonix had approximately $7.3 million of outstanding R&D contract commitments and approximately $2.039 million of future minimum lease payments. It also expanded office space and opened a California satellite office.
- Related-party transactions included acquisition of smallpox and radioprotective intellectual property from entities controlled by CEO and Chairman Seth Lederman, for cash and shares, and an employment agreement with him. These transactions merit review for terms, valuation, and governance.
- Management reported disclosure controls were effective at June 30, 2014 and no material change in internal control over financial reporting during the quarter. The company reported no material legal proceedings.
Important facts for investors to verify
- BESTFIT results, the planned trial timelines, and the regulatory path and evidence requirements for each candidate.
- Cash runway assumptions relative to rising development costs, contract commitments, and the possibility of additional financing and dilution.
- Terms and independent oversight of related-party intellectual-property acquisitions and executive compensation.
- Share dilution: 9,933,106 shares were outstanding at June 30; the July offering added 657,000 shares, and warrants and options remained outstanding.